Volume 12, Issue 10 (11-2014)                   IJRM 2014, 12(10): 713-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Saharkhiz N, Akbari Sene A, Salehpour S, Tamimi M, Vasheghani Farahani M, Sheibani K. Treatment results of high dose cabergoline as an adjuvant therapy in six patients with established severe ovarian hyper stimulation syndrome. IJRM. 2014; 12 (10) :713-0
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-481-en.html
1- Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Iran University of medical Sciences, Shahid Akbar-abadi Hospital IVF Center, Tehran, Iran
3- Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran , saghar.salehpour@yahoo.com
4- Department of Obstetrics and Gynecology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5- Research and Development Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (450 Views)
Background: The beneficial role of cabergoline as a prophylactic agent to prevent ovarian hyper stimulation syndrome (OHSS) among high-risk patients has been demonstrated in previous studies. But data for its role as a treatment for established severe OHSS is still limited. We represent the treatment results of high dose oral cabergoline in management of six patients after the syndrome is established.
Case: High-dose oral cabergoline (1 mg daily for eight days) was prescribed as an adjuvant to symptomatic treatment for six hospitalized patients with established severe OHSS following infertility treatment cycles. In two cases OHSS resolved rapidly despite the occurrence of ongoing pregnancy.
Conclusion: Considering the treatment outcomes of our patients, high dose cabergoline did not eliminate the need for traditional treatments, but it was a relatively effective and safe therapy in management of established severe OHSS, and prevented the increase in its severity following the occurrence of pregnancy.
Full-Text [PDF 90 kb]   (165 Downloads) |   |   Full-Text (HTML)  (38 Views)  
Type of Study: Original Article |

References
1. Whelan 3rd JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 883-896. [DOI:10.1016/S0015-0282(00)00491-X]
2. Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome." Hum Reprod Update 2008; 14: 321-333. [DOI:10.1093/humupd/dmn008]
3. Busso CE, Garcia-Velasco JA, Simon C, Pellicer A. Prevention of OHSS: Current strategies and new insights. Middle East Fertil Soc J 2010; 15: 223- 230. [DOI:10.1016/j.mefs.2010.06.013]
4. Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005; 122: 127-128.
5. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006; 147: 5400-5411. [DOI:10.1210/en.2006-0657]
6. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012; 2: CD008605.
7. Ata B, Seyhan A, Orhaner S, Urman B. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009; 92: 1168. [DOI:10.1016/j.fertnstert.2009.05.021]
8. Navot D, Bergh P, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249-261. [DOI:10.1016/S0015-0282(16)55188-7]
9. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002; 143: 4339-4348. [DOI:10.1210/en.2002-220204]
10. Gómez R, Simón C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003; 68: 2164-2171. [DOI:10.1095/biolreprod.102.010801]
11. Alvarez C, Marti-Bonmati L, Novella-Maestre E, Sanz R, Gomez R, Fernandez-Sanchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92: 2931-2937. [DOI:10.1210/jc.2007-0409]
12. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008; 17: 751-755. [DOI:10.1016/S1472-6483(10)60401-4]
13. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod 2001; 16: 2263-2266. [DOI:10.1093/humrep/16.11.2263]
14. Tsunoda T, Shibahara H, Hirano Y, Suzuki T, Fujiwara H, Takamizawa S, et al. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol 2003; 17: 281-286.
15. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7: 180-183. [DOI:10.1093/oxfordjournals.humrep.a137613]
16. Rollene N, Amols M, Hudson S, Coddington C. Treatment of ovarian hyperstimulation syndrome utilizing a using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 2009; 92: 1169. [DOI:10.1016/j.fertnstert.2009.05.062]
17. Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J, Simon C, et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007; 22: 3210-3214. [DOI:10.1093/humrep/dem315]
18. Halperin I, Aller J, Varela C, Mora M, Abad A, Doltra A, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf) 2012; 77: 275-280. [DOI:10.1111/j.1365-2265.2012.04349.x]
19. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009; 70: 104-108. [DOI:10.1111/j.1365-2265.2008.03458.x]
20. Motta T, de Vincentiis S, Marchini M, Colombo N, D'Alberton A. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril 1996; 65: 440-442. [DOI:10.1016/S0015-0282(16)58113-8]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb